

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450,
ON January 26, 2004

Audrey Boyd
January 26, 2004
DATE

Attorney Docket No. B45070-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Friede, et al.	January 26, 2004
Serial No.:	09/819,464	Group Art Unit No.: 1648
Filed:	March 28, 2001	Examiner: Z. Lucas
For:	VACCINES	

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Supplemental Information Disclosure Statement Under 37 C.F.R. §1.97(c)

The attached list of citations is being submitted under the provisions of 37 C.F.R. §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein, however, should not be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention.


The references cited herein are listed on the enclosed PTO Form 1449. Copies of each are enclosed.

This statement is being filed under the provisions of 37 C.F.R. §1.97(c), before the mailing date of a Final Office action or before the mailing date of a Notice of Allowance, along with authorization to charge the \$180.00 fee specified in 37 C.F.R. §1.17(p) to the Deposit Account No. 19-2570.

Serial No.: 09/819,464
Group Art Unit No.: 1648

Please charge any additional fees under 37 C.F.R. §1.16 or §1.17 which may be required by this paper, or credit any overpayment, to the indicated Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Jeffrey A. Sutton', written over the printed name.

Jeffrey A. Sutton
Attorney for Applicants
Registration No. 34,028

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6316
Facsimile (610) 270-5090
n:\jas\pto\b45070-1\ids fee required.doc

Form PTO-1449
U.S. Department of Commerce
Patent and Trademark OfficeATTY. DOCKET NO.
B45070-1SERIAL NO.
09/819,464**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT***(Use several sheets if necessary)*APPLICANT
Friede, et al.FILING DATE
March 28, 2001GROUP
1648**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	5,057,540	10/15/91	Kensil, et al.	514	25	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 96/11711	4/25/96	PCT				
	0 231 039	8/5/87	EP				
	WO 90/03184	4/5/90	PCT				
	WO 99/12565	3/18/99	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Lipford et al., "Vaccination with Immunodominant Peptides Encapsulated in Quil A-Containing Liposomes Induces Peptide-Specific Primary CD8+ Cytotoxic T Cells". <i>Vaccine</i> , 12: 73-80 (1994).
	Vogel et al., "A Compendium of Vaccine Adjuvants and Excipients". <i>Vaccine Design: The Subunit and Adjuvant Approach</i> . Chapter 7 – Quil A and QS-21 datasheets. Eds. Powell & Newman, Plenum Press. (1995).
	Kensil et al., "Structural and Immunological Characterization of the Vaccine Adjuvant QS-21". <i>Vaccine Design: The Subunit and Adjuvant Approach</i> . Chapter 22, pp. 525-541. Eds. Powell & Newman, Plenum Press (1995).
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.